A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
NCT02579226
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumours
Interventions
DRUG:
AZD2811
Sponsor
AstraZeneca